Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIQ861 Hemodynamic Study in PAH
NCT03884465Phase 2Terminated
- Sponsor
- Liquidia Corporation
- Start
- Nov 2019
- Primary completion
- Dec 2020
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by Liquidia Corporation. Started Nov 2019; status: terminated.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03884465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03884465.